Paraoxonase-1 and Simvastatin Treatment in Patients with Stable Coronary Artery Disease

Table 4

The effect of Q192R and L55M polymorphisms on serum PON1 activity before and after treatment with simvastatin.

Genotype	CAD group					Controls
	PON1 activity (U/L)					PON1 activity (U/L)
		At baseline	After 6 months	After 12 months			At baseline	After 12 months
All subjects	53	126.58 ± 85.95	125.46 ± 93.13	122.85 ± 87.71	0.65	53	125.94 ± 79.56	128.34 ± 86.8	0.32
192QQ	32	66.04 ± 9.64	62.67 ± 9.69	64.6 ± 9.37	0.11	31	72.28 ± 14.19	70.9 ± 16.54	0.23
192QR	17	196.54 ± 48.24	204.33 ± 13.74	195.50 ± 18.53	0.7	18	182.76 ± 40.5	193.56 ± 10.12	0.38
192RR	4	302.75 ± 91.65	304.25 ± 63.23	287 ± 75.97	0.36	4	313.75 ± 72.28	327 ± 40.52	0.27
192R allele carriers	21	215.05 ± 70.35	220.5 ± 14.9	215.83 ± 18.6	0.38	22	207.71 ± 67.23	220.25 ± 16.32	0.22
55LL	14	126.13 ± 77.26	126.13 ± 77.26	129.66 ± 25.57	0.76	18	136.06 ± 83.35	151.71 ± 92.07	0.87
55LM	31	113.85 ± 68.6	111.87 ± 13.56	104.43 ± 12.4	0.22	18	112.8 ± 69.43	123.58 ± 69.43	0.81
55MM	8	163.9 ± 134.64	155.9 ± 40.35	159.00 ± 45.92	0.79	17	122.82 ± 95.62	133.56 ± 105.29	0.45

Data is presented as arithmetic means ± SD; ANOVA Friedman test; Wilcoxon signed-rank test.